We intend to bridge the gap between academia and pharmaceutical companies, especially by enabling R&D and preclinical proof of concept studies. The company is a spin-off from the Medical University Vienna,Institute of Pathophysiology and Allergy ResearchCenter of Pathophysiology, Infectiology and Immunology, with a tradition of excellency in science, especially in the fields allergology and immunology. The pole position at the General Hospital allows tight interactions with clinical departments and translational studies. Biomedical Int. R+D also cooperates with a translational research platform at the University of Veterinary Medicine Vienna.